Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck to co-promote Merck’s type 2 diabetes therapies Januvia and its family of products in long-term care institutions in the U.S.   Avanir’s institutional sales force will promote the sitagliptin family of products to health care practitioners beginning in October 2013. Avanir will be compensated via a fixed fee plus an incentive-based payment. Merck will continue to be responsible for the promotion of ...